Office of Continuing Competency and Assessment, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Family Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Can J Diabetes. 2019 Oct;43(7):498-503. doi: 10.1016/j.jcjd.2019.04.008. Epub 2019 Apr 26.
The care of patients with diabetes mellitus (DM), compiled in the 2008 Canadian Diabetes Association clinical practice guidelines and in recommendations from the Choosing Wisely Canada program, is informed by a large body of evidence. This study sought to assess to what extent primary care providers (PCPs) incorporate recommended statin and sulfonylureas treatment in their care of patients with DM, and to identify the association between use of recommended care and PCP characteristics.
This retrospective cohort study (2007-2017) used electronic medical records of 21,149 patients with DM receiving care from 240 PCPs participating in the Manitoba Primary Care Research Network.
PCPs prescribed statins to patients newly diagnosed with DM who were ≥40 years of age 41% of the time, with 45% of the prescriptions occurring ≤180 days after a new diagnosis (early treatment). PCPs least likely to prescribe recommended statin treatment had higher odds of being older (adjusted odds ratio [aOR], 1.05; 95% confidence interval [CI], 1.01 to 1.09) and fee-for-service funded (aOR, 4.36; 95% CI, 1.47 to 12.91). In addition, older PCPs (aOR, 1.06; 95% CI, 1.02 to 1.10) and women (aOR, 2.42; 95% CI, 1.11 to 5.28) were less likely to prescribe statin treatment early. Seventy-four percent of PCPs prescribed sulfonylureas to adults ≥65 years of age. No PCP characteristics were associated with prescription of sulfonylureas in the lower implementation quartile in the fully adjusted model.
Results suggest that PCPs' practice does not always align with current evidence-based clinical guidelines or Choosing Wisely Canada recommendations for patients with DM. Some PCP's characteristics were associated with lower implementation of recommended evidence-based care. This information can help guide future targeted medical education.
2008 年加拿大糖尿病协会临床实践指南和明智选择加拿大计划的建议中汇集了糖尿病患者的护理,这是基于大量证据的。本研究旨在评估初级保健提供者(PCP)在其对糖尿病患者的护理中多大程度上纳入了推荐的他汀类药物和磺脲类药物治疗,并确定推荐护理的使用与 PCP 特征之间的关联。
这项回顾性队列研究(2007-2017 年)使用了参与马尼托巴省初级保健研究网络的 240 名 PCP 为 21149 名新诊断为糖尿病的患者提供的电子病历。
PCP 为≥40 岁的新诊断为糖尿病的患者开具他汀类药物的处方,有 41%的时间符合推荐治疗,其中 45%的处方发生在新诊断后≤180 天内(早期治疗)。最不可能开具推荐他汀类药物治疗的 PCP 更有可能年龄较大(调整后的优势比 [aOR],1.05;95%置信区间 [CI],1.01 至 1.09)和按费用支付(aOR,4.36;95%CI,1.47 至 12.91)。此外,年龄较大的 PCP(aOR,1.06;95%CI,1.02 至 1.10)和女性(aOR,2.42;95%CI,1.11 至 5.28)不太可能早期开具他汀类药物治疗。74%的 PCP 为≥65 岁的成年人开具磺脲类药物。在完全调整后的模型中,没有 PCP 特征与较低实施四分位的磺脲类药物处方相关。
结果表明,PCP 的实践并不总是与糖尿病患者的当前基于证据的临床指南或明智选择加拿大建议一致。一些 PCP 的特征与推荐的基于证据的护理的较低实施相关。这些信息可以帮助指导未来有针对性的医学教育。